News-Medical.Net on MSN
Low-dose megestrol strengthens hormone therapy in ER-positive breast cancer
Low-dose megestrol enhances hormone therapy for ER-positive breast cancer, reducing tumor proliferation and improving ...
Tukysa (tucatinib) may represent a new patient-friendly option as a first line maintenance treatment possibility for patients ...
"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...
HER2CLIMB-05 trial evaluated Tukysa in combination with Herceptin and Perjeta for HER2-positive metastatic breast cancer, ...
SurvivorNet on MSN
The evERA Trial: A Promising Treatment Option For Patients With Estrogen Receptor-Positive (ER+), HER2-Negative (HER2-) Breast Cancer
The evERA breast cancer trial marks a turning point for some patients with a specific type of advanced breast cancer known as ...
Hosted on MSN
Study: Pre-operative THP leads to pCR in 64% of early-stage HER2+ ER- breast cancer patients
Patients with Stage II and III (early-stage) HER2+ breast cancer usually undergo preoperative therapy with multi-agent chemotherapy in combination with anti-HER2 antibodies, followed by surgery. A ...
Imlunestrant is approved for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, showing improved progression-free survival with abemaciclib. The oral administration of ...
Patients with Stage II and III (early-stage) HER2+ breast cancer usually undergo pre-operative therapy with multi-agent chemotherapy in combination with anti-HER2 antibodies, followed by surgery. A ...
—There was no significant difference in invasive disease-free survival between patients with human epidermal growth factor receptor 2-positive (HER2+) T1micN0 breast cancer who were and were not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback